MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines.

ABSTRACT:

Background

Ovarian cancer is the leading cause of death from gynecologic cancer in women worldwide. According to the National Cancer Institute, ovarian cancer has the highest mortality rate among all the reproductive cancers in women. Advanced stage diagnosis and chemo/radio-resistance is a major obstacle in treating advanced ovarian cancer. The most commonly employed chemotherapeutic drug for ovarian cancer treatment is cis-platin. As with most chemotherapeutic drugs, many patients eventually become resistant to cis-platin and therefore, diminishing its effect. The efficacy of current treatments may be improved by increasing the sensitivity of cancer cells to chemo/radiation therapies.

Methods

The present study is focused on identifying the differential expression of regula

SUBMITTER: Kumar S 

PROVIDER: S-EPMC3205057 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature